The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Therapeutic Targeting Of The Hedgehog Signaling Pathway In Premalignant Lesions Of The Breast.
Funder
National Health and Medical Research Council
Funding Amount
$115,980.00
Summary
Breast screening has been successful in reducing deaths from breast cancer. Unfortunately it also detects increasing numbers of precancerous changes. Treatment of these changes is often aggressive, using surgery and radiotherapy. However we are unable to predict exactly which of the changes we need to treat. We aim to better understand the changes involved in this progression and try to block them using new drugs.
Investigating The Cellular Requirement For STIM1 Phosphorylation And Store-operated Calcium Entry Suppression During Mitosis: Roles In Development And Cancer
Funder
National Health and Medical Research Council
Funding Amount
$344,900.00
Summary
Cells are constantly interacting with and modifying their surrounding environment. The intracellular calcium signal is one mechanism cells use to translate signals from the microenvironment into cellular responses. This proposal seeks to explore why a key calcium signalling pathway, known as store-operated calcium entry, is specifically silenced during cell division, and to determine how reversing this inhibition affects cell division during normal development and in cancer.
Understanding The Molecular Heterogeneity Of Response And Resistance To Anti-HER2-ErbB2 Agents In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$373,173.00
Summary
A revolution in cancer care will take place in the next decade as we aim to individualize treatment for each patient. A subtype of breast cancer relies on a growth factor called HER2 for growth. Treatments that block HER2 are highly effective and have less side effects than chemotherapy. My study aims to further understand of the biology of this subtype of breast cancer and action of anti-HER2 agents as this will allow us to treat this aggressive type of breast cancer more effectively.